Sign In
Buy ALC
$67.81
+0.670 (+1.00%)
At Close: Jul 10, 2026
Alcon & RxSight Collaborate to Develop Adjustable PCIOL Technology
10:40am, Monday, 13'th Jul 2026
ALC is developing adjustable presbyopia-correcting lenses that pair advanced optics with post-surgery light adjustment.
DELL & 3 More Stocks With Strong Interest Coverage to Buy Now
09:56am, Monday, 13'th Jul 2026
DELL, Brinker International, Tapestry and Alcon pair strong interest coverage with solid growth prospects amid elevated borrowing costs.
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook
10:02pm, Friday, 10'th Jul 2026
RxSight NASDAQ: RXST reported preliminary second-quarter financial results and provided updates on its product pipeline following a newly announced strategic collaboration agreement with Alcon, with m
Wall Street Analysts Predict a 27.75% Upside in Alcon (ALC): Here's What You Should Know
10:56am, Thursday, 09'th Jul 2026
The mean of analysts' price targets for Alcon (ALC) points to a 27.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in
ALC vs. IDXX: Which Stock Is the Better Value Option?
12:41pm, Tuesday, 07'th Jul 2026
Investors looking for stocks in the Medical - Instruments sector might want to consider either Alcon (ALC) or Idexx Laboratories (IDXX). But which of these two companies is the best option for those l
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
04:15pm, Monday, 06'th Jul 2026
ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc. (NASDAQ: RXST), an ophthalmic
Here's Why Alcon (ALC) is a Strong Momentum Stock
10:51am, Monday, 06'th Jul 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
03:16pm, Thursday, 02'nd Jul 2026
Alcon's new platforms, lenses and dry eye momentum support growth, but macro pressures, tariffs and fierce competition weigh on its outlook.
MiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board of Directors
09:04am, Monday, 29'th Jun 2026
David Endicott, Chief Executive Officer of Alcon, brings global healthcare leadership and public company experience; Linnea Burman adds MedTech operating depth NORTHRIDGE, Calif., June 29, 2026 /PRNew
Alcon (ALC) is a Top-Ranked Value Stock: Should You Buy?
10:41am, Monday, 22'nd Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alcon Launches UNITY® CS at COS 2026, Advancing the Next Generation of Surgical Innovation in Canada
09:43am, Monday, 15'th Jun 2026
MONTRÉAL--(BUSINESS WIRE)--Alcon announces the launch and Canadian availability of UNITY® Cataract System (CS), Alcon's next-generation standalone cataract surgical platform.
Mexican Gold Announces Subscription Receipt Financing and Loan to Alcon Silver in Connection with Arrangement
07:00am, Monday, 15'th Jun 2026
Vancouver, British Columbia--(Newsfile Corp. - June 15, 2026) - Mexican Gold Mining Corp. (TSXV: MEX) ("Mexican Gold" or the "Company") and Alcon Silver Corp. ("Alcon") announce that, in connection
Is It Too Late to Buy Alcon Inc (ALC) After 3.7% Rally? GF Value Says Undervalued
05:53pm, Thursday, 04'th Jun 2026
On June 04, 2026, Alcon Inc (ALC) shares rose 3.7% today, closing at $66.58. The stock has seen considerable volatility over the past year, with a 52-week high
Alcon: Product Cycle Reset Creates An Attractive Entry Point (Initiating Buy)
06:11am, Sunday, 31'st May 2026
Alcon receives a buy rating, driven by the launch of Tryptyr in the mature dry eye disease market. Tryptyr's unique mechanism and rapid tear production differentiate it, but commercial adoption hinges
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
11:06am, Thursday, 28'th May 2026
Alcon's Surgical and Vision Care units returned to 6% growth in Q1 2026, but tariffs, macro pressure and fierce competition still loom.
